"For the millions of individuals affected by recurrent genital herpes, current therapies fall short in managing the significant impact repeated outbreaks have on their lives," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "With the Phase 1b study of ABI-1179 now underway, we look forward to evaluating viral and clinical outcomes for both promising long-acting HSV investigational therapies, ABI-5366 and ABI-1179, and we remain on track for interim data from both studies in the fall of thi ...